Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nebivolol
Drug ID BADD_D01541
Description Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity.[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].[A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.[A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Indications and Usage For the treatment of essential hypertension.
Marketing Status Prescription; Discontinued
ATC Code C07AB12
DrugBank ID DB04861
KEGG ID D05127
MeSH ID D000068577
PubChem ID 71301
TTD Drug ID D0Z1UA
NDC Product Code 51407-485; 13668-355; 65977-0048; 51407-484; 72241-035; 59651-138; 50090-5761; 31722-588; 71209-058; 62559-275; 31722-587; 67877-392; 62559-276; 59651-139; 72241-032; 27241-179; 27241-182; 51407-486; 71209-059; 71209-061; 51407-483; 0904-7225; 50090-5708; 50090-5752; 67877-391; 67877-390; 62559-278; 0904-7190; 31722-585; 27241-181; 0904-7226; 13668-353; 50090-5775; 72241-034; 71209-060; 67877-393; 13668-354; 27241-180; 31722-586; 13668-356; 59651-137; 72241-033; 62559-277; 59651-140; 0904-7189
Synonyms Nebivolol | Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol | Bystolic | Nebilet | Silostar | Nebivolol Hydrochloride | Hydrochloride, Nebivolol | R 67555 | 67555, R | R-67555 | R67555 | Lobivon
Chemical Information
Molecular Formula C22H25F2NO4
CAS Registry Number 99200-09-6
SMILES C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal pain15.03.04.0070.000477%
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.0030.000477%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.001192%
Pain08.01.08.004--
Pain in extremity15.03.04.0100.000477%
Palpitations02.01.02.0030.000953%
Paraesthesia17.02.06.0050.000715%
Peripheral ischaemia24.04.03.002--
Platelet count decreased13.01.04.001--
Pruritus23.03.12.0010.000715%
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Rash23.03.13.0010.002383%Not Available
Raynaud's phenomenon24.04.03.003--Not Available
Renal failure20.01.03.0050.000249%Not Available
Seizure17.12.03.0010.000477%
Shock24.06.02.002--Not Available
Skin discolouration23.03.03.0050.000477%Not Available
Skin disorder23.03.03.007--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.000715%
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000715%
Urticaria23.04.02.001; 10.01.06.0010.000715%
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Weight decreased13.15.01.0050.000953%
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages